Abstract
Purpose: The purpose of this study was to report functional and morphologic retinal changes after intravitreal injections of 0.5 mg ranibizumab in patients with myopic neovascular membrane (choroidal neovascularization). Methods: This is a case review of 11 consecutive patients with myopic choroidal neovascularization who received intravitreal injections of ranibizumab at monthly intervals. Serial changes in best-corrected visual acuity, optical coherence tomography, fluorescein angiography, and microperimetry (Nidek MP1, Nidek, Padova, Italy) are presented. Results: Mean baseline best-corrected visual acuity was 59.82 ± 17.50 Early Treatment Diabetic Retinopathy Study letters. After a follow-up of 36 weeks, mean visual acuity improved to 66.72 ± 17.3 with a mean change of 6.91 letters. Mean baseline retinal sensitivity was 6.02 ± 1.9 dB. After 36 weeks, mean sensitivity improved to 8.3 ± 2.4 dB with a mean change of 2.3 dB. The fixation stability improved from 45.5% to 72.7%. All patients also had complete resolution of subretinal fluid, mean optical coherence tomography central retinal thickness was reduced from 244.64 ± 39.3 μm to 191.36 ± 27.3 μm at 36 weeks, and fluorescein angiography at 36 weeks showed absence of leakage in all patients. Conclusion: Intravitreal ranibizumab injections seemed to positively influence retinal functional status in patients with myopic choroidal neovascularization.
| Original language | English |
|---|---|
| Pages (from-to) | 413-417 |
| Number of pages | 5 |
| Journal | Retina |
| Volume | 30 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2010 |
Fingerprint
Keywords
- Anti-VEGF drugs
- Choroidal neovascularization
- CNV
- Microperimetry
- Myopic CNV
- Pathologic myopia
- Ranibizumab
- Retinal sensitivity
- Vascular endothelial growth factor
ASJC Scopus subject areas
- Ophthalmology
Cite this
Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab. / Varano, Monica; Tedeschi, Massimiliano; Oddone, Francesco; Perillo, Loredana; Coppè, Andrea Maria; Parravano, Mariacristina.
In: Retina, Vol. 30, No. 3, 03.2010, p. 413-417.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab
AU - Varano, Monica
AU - Tedeschi, Massimiliano
AU - Oddone, Francesco
AU - Perillo, Loredana
AU - Coppè, Andrea Maria
AU - Parravano, Mariacristina
PY - 2010/3
Y1 - 2010/3
N2 - Purpose: The purpose of this study was to report functional and morphologic retinal changes after intravitreal injections of 0.5 mg ranibizumab in patients with myopic neovascular membrane (choroidal neovascularization). Methods: This is a case review of 11 consecutive patients with myopic choroidal neovascularization who received intravitreal injections of ranibizumab at monthly intervals. Serial changes in best-corrected visual acuity, optical coherence tomography, fluorescein angiography, and microperimetry (Nidek MP1, Nidek, Padova, Italy) are presented. Results: Mean baseline best-corrected visual acuity was 59.82 ± 17.50 Early Treatment Diabetic Retinopathy Study letters. After a follow-up of 36 weeks, mean visual acuity improved to 66.72 ± 17.3 with a mean change of 6.91 letters. Mean baseline retinal sensitivity was 6.02 ± 1.9 dB. After 36 weeks, mean sensitivity improved to 8.3 ± 2.4 dB with a mean change of 2.3 dB. The fixation stability improved from 45.5% to 72.7%. All patients also had complete resolution of subretinal fluid, mean optical coherence tomography central retinal thickness was reduced from 244.64 ± 39.3 μm to 191.36 ± 27.3 μm at 36 weeks, and fluorescein angiography at 36 weeks showed absence of leakage in all patients. Conclusion: Intravitreal ranibizumab injections seemed to positively influence retinal functional status in patients with myopic choroidal neovascularization.
AB - Purpose: The purpose of this study was to report functional and morphologic retinal changes after intravitreal injections of 0.5 mg ranibizumab in patients with myopic neovascular membrane (choroidal neovascularization). Methods: This is a case review of 11 consecutive patients with myopic choroidal neovascularization who received intravitreal injections of ranibizumab at monthly intervals. Serial changes in best-corrected visual acuity, optical coherence tomography, fluorescein angiography, and microperimetry (Nidek MP1, Nidek, Padova, Italy) are presented. Results: Mean baseline best-corrected visual acuity was 59.82 ± 17.50 Early Treatment Diabetic Retinopathy Study letters. After a follow-up of 36 weeks, mean visual acuity improved to 66.72 ± 17.3 with a mean change of 6.91 letters. Mean baseline retinal sensitivity was 6.02 ± 1.9 dB. After 36 weeks, mean sensitivity improved to 8.3 ± 2.4 dB with a mean change of 2.3 dB. The fixation stability improved from 45.5% to 72.7%. All patients also had complete resolution of subretinal fluid, mean optical coherence tomography central retinal thickness was reduced from 244.64 ± 39.3 μm to 191.36 ± 27.3 μm at 36 weeks, and fluorescein angiography at 36 weeks showed absence of leakage in all patients. Conclusion: Intravitreal ranibizumab injections seemed to positively influence retinal functional status in patients with myopic choroidal neovascularization.
KW - Anti-VEGF drugs
KW - Choroidal neovascularization
KW - CNV
KW - Microperimetry
KW - Myopic CNV
KW - Pathologic myopia
KW - Ranibizumab
KW - Retinal sensitivity
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=77949381797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77949381797&partnerID=8YFLogxK
U2 - 10.1097/IAE.0b013e3181bd2d23
DO - 10.1097/IAE.0b013e3181bd2d23
M3 - Article
C2 - 20010453
AN - SCOPUS:77949381797
VL - 30
SP - 413
EP - 417
JO - Retina
JF - Retina
SN - 0275-004X
IS - 3
ER -